Literature DB >> 8417131

Fresh and cultured Langerhans cells display differential capacities to activate hapten-specific T cells.

R Dai1, S F Grammer, J W Streilein.   

Abstract

Langerhans cells (LC) that have been cultured for 3 days acquire potent T cell-activating properties when compared to freshly prepared, uncultured LC. By contrast, fresh LC are superior to cultured LC in the ability to process native protein Ag. To define further the disparate functional properties of these epidermally derived APC, freshly isolated and cultured epidermal cells (EC) enriched for LC were prepared from BALB/c mice. Highly purified T cells from naive mice, and from mice sensitized epicutaneously with dinitrofluorobenzene, have been examined for their capacity to respond to fresh and cultured EC; 1) in the presence of staphylococcal enterotoxin B; and 2) after the EC had been derivatized with dinitrofluorobenzene. Both fresh and cultured EC activated syngeneic T cells in the presence of staphylococcal enterotoxin B, and fresh and cultured DNP-derivatized EC induced proliferation among DNP-specific T cells. Only cultured, hapten-derivatized EC were able to activate unprimed syngeneic T cells in vitro, and these cells responded as though "primed" when re-exposed to DNP-derivatized spleen cells in secondary cultures. In addition, naive lymphocytes that were activated by cultured DNP-EC were able to evoke local contact hypersensitivity reactions when injected into the pinnae of naive mice that were then painted with dinitrofluorobenzene. By contrast, naive syngeneic T cells exposed to fresh DNP-EC neither proliferated nor differentiated into effector cells. We conclude that fresh LC can constitutively activate primed, but not unprimed, hapten-specific T cells, whereas cultured LC readily both primed and unprimed T cells. The capacity of hapten-derivatized cultured EC to convert naive, hapten-specific T cells into cells that mediate contact hypersensitivity supports the proposal that cultured LC are the functional equivalents of epidermal LC that have migrated to draining lymph nodes. The ability of hapten-derivatized fresh LC to activate primed, hapten-specific T cells is consistent with the view that fresh LC are functionally equivalent to LC within the epidermis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417131

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin.

Authors:  B Hasséus; M Jontell; G Bergenholtz; U I Dahlgren
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Cultured human Langerhans' cells are superior to fresh cells at presenting native HIV-1 protein antigens to specific CD4+ T-cell lines.

Authors:  G Girolomoni; M T Valle; V Zacchi; M G Costa; A Giannetti; F Manca
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 3.  Contact dermatitis. Clinical perspectives and basic mechanisms.

Authors:  A Nasir; A A Gaspari
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

4.  Distinct roles for transforming growth factor-beta2 and tumour necrosis factor-alpha in immune deviation elicited by hapten-derivatized antigen-presenting cells.

Authors:  K H Hecker; H Niizeki; J W Streilein
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

5.  Dermal toxicity: alternative methods for risk assessment.

Authors:  A M Goldberg; H I Maibach
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

6.  Sensitizing capacity of Langerhans' cells obtained from ultraviolet-B-exposed murine skin.

Authors:  R Dai; J W Streilein
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

Review 7.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.